Skip to main content
Sinocelltech Group Limited logo

Sinocelltech Group Limited — Investor Relations & Filings

Ticker · 688520 ISIN · CNE100003ZL3 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 659 across all filing types
Latest filing 2021-08-25 Proxy Solicitation & In…
Country CN China
Listing Shanghai Stock Exchange 688520

About Sinocelltech Group Limited

https://www.sinocelltech.com/

Sinocelltech Group Limited focuses on the research, development, and commercialization of innovative biologics, including monoclonal antibodies, recombinant proteins, and vaccine candidates. The company's product pipeline addresses therapeutic areas such as oncology, autoimmune disorders, hematology, and infectious diseases. Key offerings include recombinant human coagulation factor VIII for hemophilia A and a range of biosimilars. Sinocelltech leverages an integrated technology platform encompassing early-stage discovery through to large-scale industrial production. This infrastructure supports the development of high-quality biological medicines aimed at addressing unmet medical needs through advanced protein engineering and cell line development.

Recent filings

Filing Released Lang Actions
神州细胞关于召开2021年第二次临时股东大会的通知
Proxy Solicitation & Information Statement Classification · 95% confidence The document is a notice about convening the 2021 second extraordinary general meeting of shareholders for Beijing Shenzhou Cell Biotechnology Group Co., Ltd. It includes details about the meeting date, voting methods, agenda items, registration procedures, and an authorization letter for proxy voting. There are no financial statements, earnings data, or management discussion of financial results. The document is an announcement informing shareholders about the meeting and how to participate, rather than the report or results of the meeting itself. It is not a full annual or interim report, nor a voting results declaration. Given the content and length (3337 characters), it fits the category of a Proxy Solicitation & Information Statement (PSI), which includes materials sent to shareholders to provide information and request votes for meetings.
2021-08-25 Chinese
神州细胞2021年半年度报告
Interim / Quarterly Report Classification · 100% confidence The document is titled "2021 年半年度报告" which translates to "2021 Semi-Annual Report." It covers a six-month period from January 1, 2021, to June 30, 2021, as indicated in the definitions section. The content includes detailed financial data, management discussion and analysis, company overview, industry analysis, and operational details. The length is substantial (15,000 characters), and it contains actual financial statements and substantive financial data. The document is clearly a comprehensive interim financial report for a period shorter than a full fiscal year, matching the definition of an Interim / Quarterly Report (IR). H1 2021
2021-08-25 Chinese
神州细胞关于使用暂时闲置募集资金进行现金管理的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement by Beijing Shenzhou Cell Biotechnology Group Co., Ltd. regarding the use of temporarily idle raised funds for cash management. It details the board and supervisory committee approvals, investment purpose, amount, duration, risk control measures, and opinions from independent directors and the supervisory board. The document is a formal disclosure about the company's use of raised funds, specifically addressing compliance with regulatory requirements and shareholder interests. It does not contain financial statements or detailed financial performance data, nor is it a report or transcript. It is a regulatory announcement about capital management related to fundraising proceeds. Therefore, it fits best under Capital/Financing Update (CAP). The document length is 3080 characters, which is typical for an announcement rather than a full report.
2021-08-25 Chinese
神州细胞2021年半年度募集资金存放与实际使用情况的专项报告
Capital/Financing Update Classification · 95% confidence The document is a detailed report on the management and actual use of funds raised by Beijing Shenzhou Cell Biotechnology Group Co., Ltd. for the half-year period ending June 30, 2021. It includes specifics on the amount raised, usage of funds, interest income, cash management, and compliance with regulatory requirements. The document references regulatory guidelines related to the management and use of raised funds and provides a comprehensive breakdown of fund usage and balances. It is not a general annual or quarterly financial report, nor is it an announcement or a brief summary. The content aligns with a specialized report on capital raising and fund usage, which fits the category of Capital/Financing Update (CAP). The document length (6800 characters) and detailed financial data support this classification rather than a simple announcement or regulatory filing.
2021-08-25 Chinese
中信证券股份有限公司关于北京神州细胞生物技术集团股份公司增加2021年度申请授信额度并提供担保的核查意见
Capital/Financing Update Classification · 95% confidence The document is a detailed verification opinion from a sponsoring institution (中信证券股份有限公司) regarding the increase in credit application limits and provision of guarantees for the year 2021 by 北京神州细胞生物技术集团股份公司. It includes descriptions of the credit limits, guarantees, internal decision procedures, financial data of the guaranteed entity, and opinions from the board and independent directors. The document is not a financial report itself but a formal verification and opinion related to financing activities and guarantees. It does not contain financial statements or earnings data but focuses on credit and guarantee approvals and related corporate governance procedures. This fits best under Capital/Financing Update (CAP) as it concerns updates on company financing activities and credit guarantees.
2021-08-25 Chinese
神州细胞关于增加2021年度申请授信额度并提供担保的公告
Capital/Financing Update Classification · 95% confidence The document is an official announcement from Beijing Shenzhou Cell Biotechnology Group Co., Ltd. regarding an increase in the 2021 credit application limit and provision of guarantees. It details the company's board resolutions, independent director opinions, financial data of the guaranteed subsidiary, and procedural compliance. The content focuses on financing activities, specifically the application for additional credit facilities and guarantees for a subsidiary, including the approval process and rationale. There are no financial statements or comprehensive financial performance data typical of annual or interim reports. The document is not a report itself but an announcement about financing and guarantee arrangements requiring shareholder approval. Therefore, it fits best under the category of Capital/Financing Update (CAP). The document length is 4065 characters, which is sufficient to contain substantive information rather than a mere brief notice or report publication announcement.
2021-08-25 Chinese

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.